HomeCompareQUVU vs JNJ

QUVU vs JNJ: Dividend Comparison 2026

QUVU yields 2.01% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QUVU wins by $2.6K in total portfolio value
10 years
QUVU
QUVU
● Live price
2.01%
Share price
$26.91
Annual div
$0.54
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.6K
Annual income
$228.38
Full QUVU calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — QUVU vs JNJ

📍 QUVU pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQUVUJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QUVU + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QUVU pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QUVU
Annual income on $10K today (after 15% tax)
$170.51/yr
After 10yr DRIP, annual income (after tax)
$194.12/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $509.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QUVU + JNJ for your $10,000?

QUVU: 50%JNJ: 50%
100% JNJ50/50100% QUVU
Portfolio after 10yr
$21.3K
Annual income
$528.08/yr
Blended yield
2.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

QUVU
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QUVU buys
0
JNJ buys
0
No recent congressional trades found for QUVU or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQUVUJNJ
Forward yield2.01%3.36%
Annual dividend / share$0.54$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$22.6K$20.0K
Annual income after 10y$228.38$827.78
Total dividends collected$2.2K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: QUVU vs JNJ ($10,000, DRIP)

YearQUVU PortfolioQUVU Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,901$200.60$10,676$355.77+$225.00QUVU
2$11,868$204.36$11,407$389.39+$461.00QUVU
3$12,907$207.94$12,198$426.53+$709.00QUVU
4$14,022$211.34$13,056$467.62+$966.00QUVU
5$15,218$214.58$13,987$513.12+$1.2KQUVU
6$16,500$217.65$14,998$563.56+$1.5KQUVU
7$17,876$220.56$16,098$619.52+$1.8KQUVU
8$19,351$223.31$17,295$681.69+$2.1KQUVU
9$20,931$225.92$18,599$750.82+$2.3KQUVU
10$22,625$228.38$20,022$827.78+$2.6KQUVU

QUVU vs JNJ: Complete Analysis 2026

QUVUStock

Seeks long-term capital appreciation.

Full QUVU Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this QUVU vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QUVU vs SCHDQUVU vs JEPIQUVU vs OQUVU vs KOQUVU vs MAINQUVU vs ABBVQUVU vs MRKQUVU vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.